SCHEMBL4898387

SCHEMBL4898387

CN(C)S(=O)(=O)n1cc(-c2ccc3c(c2)OCO3)c(-c2ccnc(C(F)(F)F)n2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
POLB P06746 3/20 0.40
PTGS2 P35354 3/20 0.39
PTGS1 P23219 1/20 0.39
CLK1 P49759 4/20 0.37
CLK4 Q9HAZ1 4/20 0.37
CLK2 P49760 3/20 0.37
DYRK1A Q13627 3/20 0.37
DYRK1B Q9Y463 3/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GLO1 Q04760 1/20 0.36
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5930976 0.85 PTGS2 (0.44) KDM4EALDH1A1POLBPTGS2PTGS1
SCHEMBL5930884 0.80 TGFBR1 (0.39) KDM4EALDH1A1POLBPTGS2NPC1
SCHEMBL5930950 0.78 TGFBR1 (0.37) KDM4EALDH1A1POLBPTGS2NPC1
SCHEMBL5930893 0.78 TGFBR1 (0.35) KDM4EALDH1A1POLBPTGS2NPC1
SCHEMBL4899629 0.75 IDH1 (0.34) PTGS2PTGS1CYP3A4CYP2D6CYP2C9
SCHEMBL4894431 0.73 KDM4E (0.44) KDM4EALDH1A1POLBCLK1CLK4
SCHEMBL3240693 0.63 TGFBR1 (0.59) KDM4EALDH1A1POLBSMN1; SMN2HSD17B10
SCHEMBL5930800 0.63 TGFBR1 (0.45) KDM4EALDH1A1PTGS2PTGS1NPC1
SCHEMBL5138791 0.61 TGFBR1 (0.46)
SCHEMBL5202662 0.60 PTGS2 (0.68) PTGS2PTGS1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171755-A1 Pyrimidinylpyrazoles as Tgf-Beta Inhibitors LEE WEN-CHERNG 2008-07-17 US disclosed
EP-1786803-A1 PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS Biogen Idec MA, Inc. (US) 2007-05-23 EP disclosed
WO-2006026305-A1 PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS BIOGEN IDEC MA INC (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171755-A1 Pyrimidinylpyrazoles as Tgf-Beta Inhibitors TGFBR1, SMAD3, ALK KDM4E 426/4885ALDH1A1 188/4885POLB 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.